Investors & Media

Dedicated to delivering long-term investment value.

Hero Investors2

Featured News: CSL and uniQure Win 2023 Prix Galien USA Award


At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Stock Information

Updated stock ticker information for uniQure

  • NASDAQ:
  • Price:
  • Change:
  • Volume:

(Updated every 15 minutes)

Learn More

SEC Filings

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More

Governance

Links to key uniQure corporate governance documents

Learn More

Upcoming Webcasts

No webcasts scheduled. Check back soon.

Webcast Archive

  • Guggenheim 6th Annual Biotechnology Conference
    3:00PM-3:25PM ET

    View Webcast
  • uniQure Huntington's Disease Program Update: AMT-130
    8:30 a.m. ET

    View Webcast
  • uniQure’s Virtual Research & Development Event
    8:30AM ET to 10:30 AM ET

    View Webcast
See All

Investor Presentations

  • Corporate Presentation – January 2024

    View Presentation
  • December 2023 Huntington's Disease Program Update AMT-130 – Webcast Presentation

    View Presentation
  • Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements

    View Presentation
  • CHDI 2022 – Radiographic and clinical progression after motor diagnosis in HD is a function of initial striatal volume and functional scores: a re-analysis of TRACK-HD/TRACK-ON HD MRI images and data

    View Presentation
  • ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions

    View Presentation
See All
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button